AtaiBeckley VLS-01 Phase 2b TRD data reads out positive and triggers Phase 3 initiation.

A company called Atai Beckley is testing a drug called VLS-01 for people with treatment-resistant depression — meaning people whose depression hasn't responded to standard antidepressants. The mid-size trial results look likely to come back positive, which would trigger a much larger trial needed before seeking FDA approval. This matters because treatment-resistant depression affects millions of people with very few good options.

Last-patient-dosed signals confidence; ATAI's outperformance reflects de-risking. Momentum across MDD indications validates the platform thesis.